Hubungan Dosis Dan Durasi Pemberian Atorvastatin Terhadap Outcome Terapi Pasien Penyakit Jantung Koroner

Ririn Wirawati

Abstract


Atorvastatin merupakan obat golongan statin yang lebih efektif menurunkan LDL-C dan resiko penyakit kardiovaskuler. Pemilihan dosis terapi atorvastatin yang tepat dapat menurunkan pasien untuk mencapai target LDL <70 mg/dL sebagai parameter keberhasilan terapi. Penggunaan atorvastatin mempunyai efek maksimum dalam waktu 2 minggu dan mencapai efek stady state dalam waktu 5 hari. Tujuan dari penelitian ini adalah untuk mengetahui dosis dan durasi pemberian atorvastatin dapat mencapai outcome tarapi pasien penyakit jantung koroner  di Rumah Sakit Panti Waluyo Surakarta. Penelitian ini menggunakan metode cross sectional dengan penelusuran terhadap rekam medis pasien secara retrospektif dan dianalisis menggunakan Chi-square. Subyek penelitian ini yaitu pasien jantung koroner yang mendapatkan terapi atorvastatin minimal 1 bulan yang kemudian dilihat kadar LDL <70 mg/dL. Dari total 85 pasien diperoleh hasil analisis hubungan dosis atorvastatin (p=1,000) dan durasi atorvastatin (p=0,519) terhadap tercapainya target LDL <70 mg/dL.


Full Text:

PDF

References


Hulten, E., Jackson, J. L., Douglas, K., George, S., & Villines, T. C. (2006). The Effect of Early, Intensive Statin Therapy on Acute Coronary Syndrome. Archives of Internal Medicine, 166(17), 1814. https://doi.org/10.1001/archinte.166.17.1814

Kabo, P. (2008). Penyakit jantung koroner. Gramedia Pustaka utama.

Lewis, S.L., Dirksen, S.R., Heitkemper, M.M., Bucher, L., dan C. (2010). No TitleMedical-Surgical Nursing: Assessment and Management of Clinical Problems, 8th Edition (8th editio). Elsevier Mosby.

Mahamuni, S. P., Khose, R. D., Menaa, F., & Badole, S. L. (2012). Therapeutic approaches to drug targets in hyperlipidemia. BioMedicine, 2(4), 137–146. https://doi.org/10.1016/j.biomed.2012.08.002

Marrett, E., Zhao, C., Zhang, N. J., Zhang, Q., Ramey, D. R., Tomassini, J. E., Tershakovec, A. M., & Neff, D. R. (2014). Limitations of real-world treatment with atorvastatin monotherapy for lowering LDL-C in high-risk cardiovascular patients in the US. Vascular Health and Risk Management, 10, 237–246. https://doi.org/10.2147/VHRM.S54886

Page, R.L dan Napi, J. . (2013). Acut Coronary syndrome. In Koda-Kimble and Young’s applied Therapeutics The Clinical Use of Drug (p. 408). Phialadelphia.

Price, S.. dan Wilson, L. (2006). Patofisiologi Konsep Klinik Proses Penyakit (4th ed.). Penerbit Buku Kedokteran.

Schwartz, G. G. (2001). Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes, The MIRACL Study: A Randomized Controlled Trial. JAMA, 285(13), 1711. https://doi.org/10.1001/jama.285.13.1711

Sorrentino, M. (2012). An update on statin alternatives and adjuncts. Clinical Lipidology, 7, 721–730. https://doi.org/10.2217/clp.12.66

Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Merz, C. N. B., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-jones, D. M., Mcbride, P., Schwartz, J. S., Shero, S. T., Smith, S. C., Watson, K., Wilson, P. W. F., Anderson, J. L., Halperin, J. L., Albert, N. M., … Shen, W. (2014). ACC / AHA Prevention Guideline 2013 ACC / AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults A Report of the American College of Cardiology / American Heart Association Task Force on Practice Guidel. 1–45. https://doi.org/10.1161/01.cir.0000437738.63853.7a

Wiklund, O., Pirazzi, C., & Romeo, S. (2013). Monitoring of Lipids , Enzymes , and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy. https://doi.org/10.1007/s11886-013-0397-8

Zheng, W., Zhang, Y. J., Bu, X. T., Guo, X. Z., Hu, D. Y., Li, Z. Q., & Sun, J. (2017). LDL-cholesterol goal attainment under persistent Lipid-lowering therapy in northeast China: Subgroup analysis of the dyslipidemia international study of China (DYSIS-China). Medicine (United States), 96(46). https://doi.org/10.1097/MD.0000000000008555


Article Metrics

Abstract has been read : 363 times
PDF file viewed/downloaded: 0 times


DOI: http://doi.org/10.25273/pharmed.v4i1.8475

Refbacks

  • There are currently no refbacks.